Table 2.

Drug conjugates in clinical trial.

Drug Conjugate	Target	Phase of Study	Clinical Trial Identifier	Sponsor
Disitamab vedotin and Tisleizumab	HER-2	II	NCT05493683	The First Affiliated Hospital with Nanjing Medical University (Nanjing, China)
M9140	Carcinoembryonic antigen	I	NCT05464030	EMD Serono Research & Development Institute, Inc. (Darmstadt, Germany)
CBP-1019	Unknown	I, II	NCT05830097	Coherent Biopharma (Hefei) Co., Ltd. (Hefei, China)
BDC-1001 (Nivolumab)	HER-2	I, II	NCT04278144	Bolt Biotherapeutics Inc. (Redwood City, CA, USA)
ELU001	(FRα)	I, II	NCT05001282	Elucida Oncology (Monmouth Junction, NJ, USA)
Datopotamab deruxtecan	Unknown	II	NCT05489211	AstraZeneca (Minato City, Janpan)
SBT6050 (Cemiplimab)	HER-2	I, IB	NCT04460456	Silverback Therapeutics (Seattle, WA, USA)
TORL-3-600	Unknown	I	NCT05948826	TORL Biotherapeutics, LLC (Albuquerque, NM, USA)